Zecotek Initiates ISO Processes for Manufacturing at its Singapore Facilities
Vancouver, January 9, 2007 – Zecotek Medical Systems Inc. (TSX-Venture – ZMS; Frankfurt – W1I.F) today announced it has initiated ISO processes for manufacturing at its Singapore facilities, to comply with customer and regulatory requirement for the Company’s laser and vanadate crystal production.
The announcement follows from the acceleration of plans to bring into production several new laser lines, as well as an expansion in its planned laser crystal production to meet an early and growing demand for its proprietary RFO vanadates.
Manufacturing for the Company’s patented N-MAPD multi-pixel photon counter is presently under negotiation with one of Singapore’s leading wafer fabrication facilities. Initial production is targeted for Q3 2007. Pre-production and proto-typing of the Company’s 3D display is also taking place at the Singapore facility, with product development and manufacturing expected to be outsourced to a manufacturing and distribution partner. Negotiations with a potential partner have been initiated and previously announced.
Dr. A. Faouzi Zerrouk, Zecotek’s President and CEO said: “We moved our Company operations to Singapore to deliver added value to our shareholders. We are leveraging both on Singapore’s R&D efficiencies and support mechanisms, and secondly its strong high-tech manufacturing base. We are meeting our objectives in our new base in Singapore and strengthening our relationships to build a worldwide company which will benefit all of our shareholders.”
Zecotek Medical Systems is a bio-photonics technology company developing high-performance crystals, photo detectors, medical lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry. Founded in 2003, the company has three distinct operating divisions: medical imaging, medical lasers and 3D display and labs located in Canada, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending bio-photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders.
For additional information on Zecotek Medical Systems and our technologies please see our website at www.zecotek.com.
For additional information please contact:
Zecotek Medical Systems
CFO; VP Corporate Development
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future, please email email@example.com and mention ZMS News in the subject heading or visit the corporate website at www.zecotek.com.